Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
NL0015436031
Tue, 28.03.2023
CureVac
CureVac Announces Voting Results of Extraordinary General Meeting
TÜBINGEN, Germany / BOSTON, USA – March 28, 2023 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's e [ … ]
Tue, 28.03.2023
CureVac
CureVac Announces Voting Results of Extraordinary General Meeting
TÜBINGEN, Germany / BOSTON, USA – March 28, 2023 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's e [ … ]
Fri, 10.02.2023
CureVac
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
TÜBINGEN, Germany/BOSTON, USA – February 10, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the closing of its fol [ … ]
Fri, 10.02.2023
CureVac
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
TÜBINGEN, Germany/BOSTON, USA – February 10, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the closing of its fol [ … ]
Wed, 08.02.2023
CureVac
CureVac Announces Pricing of Upsized Public Offering of Common Shares
TÜBINGEN, Germany/BOSTON, USA – February 7, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the pricing of 27,027,028 common sha [ … ]
Wed, 08.02.2023
CureVac
CureVac Announces Pricing of Upsized Public Offering of Common Shares
TÜBINGEN, Germany/BOSTON, USA – February 7, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the pricing of 27,027,028 common sha [ … ]
Mon, 06.02.2023
CureVac
CureVac Announces Proposed Public Offering of Common Shares
TÜBINGEN, Germany/BOSTON, USA – February 6, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today that it intends to offer $200 million of its c [ … ]
Mon, 06.02.2023
CureVac
CureVac Announces Proposed Public Offering of Common Shares
TÜBINGEN, Germany/BOSTON, USA – February 6, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today that it intends to offer $200 million of its c [ … ]
Wed, 01.02.2023
CureVac
CureVac Welcomes Myriam Mendila as New Chief Development Officer
Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experience
TÜBINGEN, Germany/ BOSTON, USA – February 1, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on [ … ]
Wed, 01.02.2023
CureVac
CureVac Welcomes Myriam Mendila as New Chief Development Officer
Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experience
TÜBINGEN, Germany/ BOSTON, USA – February 1, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on [ … ]